As of 2024-07-27, the Relative Valuation of Supernus Pharmaceuticals Inc (SUPN) is (0.98) USD. This relative valuation is based on P/E multiples. With the latest stock price at 30.75 USD, the upside of Supernus Pharmaceuticals Inc based on Relative Valuation is -103.2%.
The range of the Relative Valuation is (3.29) - 1.82 USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 11.7x - 20.0x | 13.3x |
| Forward P/E multiples | 18.7x - 20.5x | 20.1x |
| Fair Price | (3.29) - 1.82 | (0.98) |
| Upside | -110.7% - -94.1% | -103.2% |
| Date | P/E |
| 2024-07-26 | -109.05 |
| 2024-07-25 | -108.80 |
| 2024-07-24 | -107.95 |
| 2024-07-23 | -106.03 |
| 2024-07-22 | -106.39 |
| 2024-07-19 | -107.27 |
| 2024-07-18 | -103.20 |
| 2024-07-17 | -102.66 |
| 2024-07-16 | -102.63 |
| 2024-07-15 | -101.88 |
| 2024-07-12 | -101.49 |
| 2024-07-11 | -101.03 |
| 2024-07-10 | -97.45 |
| 2024-07-09 | -94.65 |
| 2024-07-08 | -93.05 |
| 2024-07-05 | -92.31 |
| 2024-07-03 | -92.24 |
| 2024-07-02 | -91.39 |
| 2024-07-01 | -94.15 |
| 2024-06-28 | -94.86 |
| 2024-06-27 | -95.29 |
| 2024-06-26 | -94.76 |
| 2024-06-25 | -94.01 |
| 2024-06-24 | -95.43 |
| 2024-06-21 | -95.89 |
| 2024-06-20 | -95.04 |
| 2024-06-18 | -94.54 |
| 2024-06-17 | -92.17 |
| 2024-06-14 | -92.17 |
| 2024-06-13 | -94.19 |
| 2024-06-12 | -96.03 |
| 2024-06-11 | -92.91 |
| 2024-06-10 | -92.88 |
| 2024-06-07 | -93.12 |
| 2024-06-06 | -96.28 |
| 2024-06-05 | -97.66 |
| 2024-06-04 | -99.01 |
| 2024-06-03 | -97.91 |
| 2024-05-31 | -96.17 |
| 2024-05-30 | -94.22 |
| 2024-05-29 | -94.22 |
| 2024-05-28 | -96.00 |
| 2024-05-24 | -97.56 |
| 2024-05-23 | -98.48 |
| 2024-05-22 | -98.83 |
| 2024-05-21 | -99.47 |
| 2024-05-20 | -102.02 |
| 2024-05-17 | -103.20 |
| 2024-05-16 | -103.41 |
| 2024-05-15 | -101.92 |